8-K: Celularity Settles Dispute with Helena Global

Celularity Inc. has entered into a settlement agreement with Helena Global Investment Opportunities 1 Ltd. to resolve outstanding claims and restructure existing debt obligations.

Summary

• Celularity entered a settlement agreement with Helena Global to resolve claims related to a Series A Convertible Preferred Stock exchange and a subsequent event of default.
• The company will make an immediate cash payment of $500,000.
• The company will make five consecutive monthly payments of $100,000 each, totaling $500,000.
• Celularity is assigning its rights to a $2,500,000 promissory note from NEXGEL, Inc. to Helena Global.
• The settlement includes an amendment to the existing security agreement to secure the new payment obligations.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development because it highlights a liquidity crisis and the loss of a significant asset to resolve a default.

Positives

• Resolves an active event of default and potential litigation with a major creditor.
• Provides a structured path to clear outstanding claims through installment payments.
• Avoids immediate full repayment of the disputed debt by utilizing a non-core asset (NEXGEL note) as partial consideration.

Negatives

• Requires immediate cash outflow of $500,000, impacting liquidity.
• Commits the company to $100,000 in monthly payments for five months.
• The settlement is conditional; failure to meet any payment term results in the failure of the release of claims.
• The company loses the future cash flow associated with the $2,500,000 NEXGEL promissory note.

Risks

• Failure to make any of the five monthly installment payments constitutes an immediate event of default.
• If the settlement conditions are not met, the original claims and default status remain fully enforceable.
• Continued reliance on secured financing arrangements limits financial flexibility.

Future Outlook

The company is committed to fulfilling the installment payment schedule to satisfy the release conditions and terminate the security interest held by Helena Global.

Management Comments

• The company represents that it is solvent and expects to be able to pay its debts as they become due.

Industry Context

StockSavvy.ai notes that this settlement reflects the ongoing liquidity challenges faced by small-cap biotechnology firms, where companies often must trade future assets or cash flow to resolve debt defaults and avoid bankruptcy proceedings.

Comparison to Industry Standards

• The use of asset-backed settlements (like the NEXGEL note) is a common defensive maneuver for distressed biotech firms.
• The strict 'no cure period' for installment payments is a aggressive creditor term, typical of high-risk private placement financing.

Corporate Governance

Legal Proceedings

• The settlement resolves existing claims and alleged events of default under the October 2025 Securities Purchase Agreement.

Stakeholder Impact

• Shareholders: Potential dilution risk or loss of asset value due to the assignment of the NEXGEL note.
• Creditors: Helena Global gains priority interest in the NEXGEL note and continued security over company assets.

Next Steps

• Make immediate $500,000 payment.
• Execute five monthly $100,000 payments starting one month after May 21, 2026.
• Complete assignment of the NEXGEL note.

Key Dates

Recommendation

The company is in a distressed financial position, evidenced by a default and the need to settle via asset divestiture. Investors should be cautious of the ongoing liquidity risk.

Keywords

Celularity, CELU, Settlement Agreement, Debt Restructuring, Helena Global, NEXGEL, Default